EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group

Jana Mihályová, Anna Panovská, Martin Šimkovič, Lukáš Smolej, Martin Špaček, Tereza Shokralla, Zuzana Kubová, Jana Zuchnická, Tomáš Arpáš, Pavel Vodárek, Peter Turcsányi, Lenka Polcerová und 5 weitere

Annals of Hematology · 13.05.2026 · 105 (8)

DOI: 10.1007/s00277-026-07043-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Hematology, online erschienen am 13.05.2026. Verfasst von Jana Mihályová und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic. jana.mihalyova@fno.cz. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Hospital in Ostrava.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In relapsed/refractory (RR) chronic lymphocytic leukaemia (CLL), Bruton tyrosine kinase inhibitors (BTKi) are administered as monotherapy until disease progression. In contrast, venetoclax, a B-cell lymphoma 2 (BCL-2) protein inhibitor, is typically combined with rituximab (VenR) as a time-limited regimen. To date, neither randomized nor retrospective trials have directly compared these approaches in RR CLL, and only limited data are available comparing venetoclax plus obinutuzumab (VenObi) to BTKi in the first-line setting. We retrospectively analysed 352 patients receiving second-line therapy: 93 VenR and 259 BTKi (ibrutinib: n = 222; acalabrutinib: n = 37). Baseline characteristics were well balanced, except for a higher incidence of TP53 mutation and trisomy 12 in BTKi-treated patients. At a median follow-up of 13.8 months (VenR) and 22.1 months (BTKi), 12-month progression-free survival (PFS) and overall survival (OS) were comparable (PFS: 85.1% vs. 82.2%, p = 0.265; OS: 87.6% vs. 88.4%, p = 0.291). Estimated median PFS (45.4 vs. 37.9 months, p = 0.265) and OS (83.6 vs. 74.2 months, p = 0.291) also showed no significant differences between the VenR and BTKi cohorts. Treatment discontinuation due to adverse events before month 24 was more frequent with BTKi (22.5% with VenR vs. 34.3% with BTKi), primarily due to infections (10.6% vs. 28.6%) and disease progression (14.3% vs. 22.5%). These preliminary data suggest comparable outcomes and manageable toxicity profiles for both regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseAntineoplastic Combined Chemotherapy ProtocolsLeukemia, Lymphocytic, Chronic, B-CellRituximabSulfonamidesTyrosine Kinase InhibitorsAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdenineAntibodies, Monoclonal, HumanizedBenzamidesBridged Bicyclo Compounds, HeterocyclicPiperidinesRetrospective StudiesTreatment OutcomePyrazines

Stichwörter der Autor:innen

AcalabrutinibChronic lymphocytic leukaemiaIbrutinibRituximabVenetoclax

Substanzen

acalabrutinibAdenineAgammaglobulinaemia Tyrosine KinaseAntibodies, Monoclonal, HumanizedBenzamidesBridged Bicyclo Compounds, HeterocyclicBTK protein, humanibrutinibobinutuzumabPiperidines

Autor:innen und Institutionen

  • Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic. jana.mihalyova@fno.cz.
  • University of Ostrava, Ostrava, Czech Republic. jana.mihalyova@fno.cz.
  • Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • 4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic.
  • 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.

Förderung

  • University Hospital in Ostrava

Zitieren

APA

Mihályová, J., Panovská, A., Šimkovič, M., Smolej, L., Špaček, M., Shokralla, T., Kubová, Z., Zuchnická, J., Arpáš, T., Vodárek, P., Turcsányi, P., Polcerová, L., Chrápavá, M., Lysák, D., Brejcha, M., Móciková, H., & Doubek, M. (2026). Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group. Annals of Hematology, 105(8). https://doi.org/10.1007/s00277-026-07043-8

Vancouver

Mihályová J, Panovská A, Šimkovič M, Smolej L, Špaček M, Shokralla T, et al. Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group. Annals of Hematology. 2026;105(8). doi:10.1007/s00277-026-07043-8

BibTeX
@article{Mihlyov2026,
  author = {Mihályová, Jana and Panovská, Anna and Šimkovič, Martin and Smolej, Lukáš and Špaček, Martin and Shokralla, Tereza and Kubová, Zuzana and Zuchnická, Jana and Arpáš, Tomáš and Vodárek, Pavel and Turcsányi, Peter and Polcerová, Lenka and Chrápavá, Marika and Lysák, Daniel and Brejcha, Martin and Móciková, Heidi and Doubek, Michael},
  title = {Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {8},
  doi = {10.1007/s00277-026-07043-8}
}
Kostenlos starten →